Pieris Pharmaceuticals, Inc. (PIRS) Rating Reiterated by HC Wainwright

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Friday. They currently have a $9.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 65.14% from the company’s current price.

Separately, BidaskClub lowered Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Four investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $9.00.

Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.20 during trading hours on Friday, reaching $5.45. The company had a trading volume of 639,100 shares, compared to its average volume of 358,395. Pieris Pharmaceuticals has a 1 year low of $1.34 and a 1 year high of $6.58.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 180.85% and a negative net margin of 321.83%. The firm had revenue of $3.93 million for the quarter, compared to analyst estimates of $1.52 million. Pieris Pharmaceuticals’s revenue was up 400.3% on a year-over-year basis. analysts anticipate that Pieris Pharmaceuticals will post -0.83 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://ledgergazette.com/2017/11/13/pieris-pharmaceuticals-inc-pirs-rating-reiterated-by-hc-wainwright.html.

In related news, insider Allan Reine purchased 65,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was acquired at an average price of $4.82 per share, for a total transaction of $313,300.00. Following the transaction, the insider now directly owns 45,000 shares of the company’s stock, valued at approximately $216,900. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James A. Geraghty purchased 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was bought at an average price of $4.82 per share, with a total value of $48,200.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $48,200. The disclosure for this purchase can be found here. Company insiders own 4.05% of the company’s stock.

Several large investors have recently added to or reduced their stakes in PIRS. State Street Corp acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $2,377,000. Northern Trust Corp acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $1,625,000. Renaissance Technologies LLC acquired a new stake in Pieris Pharmaceuticals during the 1st quarter worth about $661,000. TIAA CREF Investment Management LLC acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $649,000. Finally, Vanguard Group Inc. acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $526,000. Institutional investors and hedge funds own 50.87% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply